Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use Observational Study of Xolair in Adolescents With Severe Seasonal Allergic Rhinitis
jRCT2031200378Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of omalizumab in seasonal allergic rhinitis (SAR), sponsored by Novartis. Started Jan 2021; status: completed.
02
Drugs
omalizumab
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2031200378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200378.